Overview

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Status:
Active, not recruiting

Trial end date:
2021-10-30

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within the prior 12 months treated with lenvatinib 24 mg by continuous once daily (QD) oral dosing versus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Lenvatinib